Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma

Cesar Gentille; Humaira Sarfraz; Jitesh Joshi; Jasleen Randhawa; Shilpan Shah; Sai Ravi Pingali

doi:10.1002/cnr2.1581

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma

Cesar Gentille, Humaira Sarfraz, Jitesh Joshi, Jasleen Randhawa, Shilpan Shah, Sai Ravi Pingali

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. Conclusion: In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.

Original language	English (US)
Article number	e1581
Pages (from-to)	e1581
Journal	Cancer Reports
Volume	5
Issue number	7
DOIs	https://doi.org/10.1002/cnr2.1581
State	Published - Jul 2022

Keywords

ICE
brentuximab vedotin
relapsed/refractory PTCL
romidepsin
salvage chemotherapy
Carboplatin/therapeutic use
Humans
Brentuximab Vedotin/therapeutic use
Depsipeptides/therapeutic use
Etoposide/therapeutic use
Ki-1 Antigen
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Neoplasm Recurrence, Local/drug therapy
Lymphoma, T-Cell, Peripheral/drug therapy
Ifosfamide/therapeutic use
Retrospective Studies

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cnr2.1581

Cite this

@article{12850d99cb87480792e0fb7995a56bc8,

title = "Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma",

abstract = "Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. Conclusion: In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.",

keywords = "ICE, brentuximab vedotin, relapsed/refractory PTCL, romidepsin, salvage chemotherapy, Carboplatin/therapeutic use, Humans, Brentuximab Vedotin/therapeutic use, Depsipeptides/therapeutic use, Etoposide/therapeutic use, Ki-1 Antigen, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local/drug therapy, Lymphoma, T-Cell, Peripheral/drug therapy, Ifosfamide/therapeutic use, Retrospective Studies",

author = "Cesar Gentille and Humaira Sarfraz and Jitesh Joshi and Jasleen Randhawa and Shilpan Shah and Pingali, {Sai Ravi}",

note = "Funding Information: We thank and acknowledge all the patients who were treated and included in this study. Publisher Copyright: {\textcopyright} 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.",

year = "2022",

month = jul,

doi = "10.1002/cnr2.1581",

language = "English (US)",

volume = "5",

pages = "e1581",

journal = "Cancer Reports",

issn = "2573-8348",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "7",

}

TY - JOUR

T1 - Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma

AU - Gentille, Cesar

AU - Sarfraz, Humaira

AU - Joshi, Jitesh

AU - Randhawa, Jasleen

AU - Shah, Shilpan

AU - Pingali, Sai Ravi

N1 - Funding Information: We thank and acknowledge all the patients who were treated and included in this study. Publisher Copyright: © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.

PY - 2022/7

Y1 - 2022/7

N2 - Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. Conclusion: In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.

AB - Background: Relapsed/refractory peripheral T-cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv-ICE in CD30 (+) and Ro-ICE in CD30 (−) R/R PTCL treated in “Blinded for peer review” Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV-ICE or romidepsin-ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv-ICE and 7 with Ro-ICE. Bv-ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro-ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv-ICE and three treated with Ro-ICE received transplantation. Conclusion: In our experience, treatment with Bv-ICE and Ro-ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.

KW - ICE

KW - brentuximab vedotin

KW - relapsed/refractory PTCL

KW - romidepsin

KW - salvage chemotherapy

KW - Carboplatin/therapeutic use

KW - Humans

KW - Brentuximab Vedotin/therapeutic use

KW - Depsipeptides/therapeutic use

KW - Etoposide/therapeutic use

KW - Ki-1 Antigen

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Neoplasm Recurrence, Local/drug therapy

KW - Lymphoma, T-Cell, Peripheral/drug therapy

KW - Ifosfamide/therapeutic use

KW - Retrospective Studies

UR - http://www.scopus.com/inward/record.url?scp=85126069020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126069020&partnerID=8YFLogxK

U2 - 10.1002/cnr2.1581

DO - 10.1002/cnr2.1581

M3 - Article

C2 - 35263030

AN - SCOPUS:85126069020

SN - 2573-8348

VL - 5

SP - e1581

JO - Cancer Reports

JF - Cancer Reports

IS - 7

M1 - e1581

ER -

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this